vTv Therapeutics director granted 6,000 stock options

vTv Therapeutics Inc. director Fahed Al-Marzooqi received a grant of stock options covering 6,000 shares of Class A common stock at an exercise price of $35.08 per share.

Accepted by SEC EDGAR 06/29/2026 - 04:09 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

vTv Therapeutics Inc. director Fahed Al-Marzooqi received a grant of stock options covering 6,000 shares of Class A common stock at an exercise price of $35.08 per share. These options vest on the earlier of June 26, 2027 and the 2027 annual general meeting of shareholders, conditioned on continued board service, and expire on June 26, 2036. Following this grant, his reported derivative holdings tied to this award total 19,555 options.

Insider Trade Summary

Grant/Award: 6,000 shares

Grant/Award 1 txn

Insider Al-Marzooqi Fahed

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director stock option (right to buy)	6,000	$35.08	$210K

Holdings After Transaction: Director stock option (right to buy) — 19,555 contracts (Direct)

Footnotes (1)

1. F1. The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting.

Key Figures

Option grant size: 6,000 options Exercise price: $35.08 per share Expiration date: June 26, 2036 +2 more

5 metrics

Option grant size 6,000 options Director stock option grant on June 26, 2026

Exercise price $35.08 per share Director stock option exercise price

Expiration date June 26, 2036 Option term end date

Total derivative holdings after grant 19,555 options Reported following transaction

Vesting date trigger Earlier of June 26, 2027 or 2027 AGM Vesting condition subject to continued board service

Key Terms

Director stock option (right to buy), exercise price, vesting, annual general meeting of shareholders

4 terms

Director stock option (right to buy) financial

"Director stock option (right to buy) with 6,000 underlying shares"

exercise price financial

"An exercise price of $35.08 per share applies to the options"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual general meeting of shareholders financial

"Vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did vTv Therapeutics (VTVT) director Fahed Al-Marzooqi receive in this Form 4 filing?

Director Fahed Al-Marzooqi received a grant of stock options covering 6,000 shares of vTv Therapeutics Class A common stock. The options are part of his director compensation and give him the right to buy shares at a fixed exercise price of $35.08.

What is the exercise price and term of Fahed Al-Marzooqi’s vTv Therapeutics options?

The granted director stock options have an exercise price of $35.08 per share and expire on June 26, 2036. This long term gives the director a multi-year window to decide whether to exercise the options, subject to vesting conditions.

When do Fahed Al-Marzooqi’s vTv Therapeutics director stock options vest?

The options vest on the earlier of June 26, 2027 and the date of vTv Therapeutics’ 2027 annual general meeting of shareholders. Vesting is subject to his continued service on the board of directors through that vesting date.

How many vTv Therapeutics derivative securities does Fahed Al-Marzooqi hold after this grant?

After the grant, the Form 4 reports total derivative holdings of 19,555 options related to vTv Therapeutics Class A common stock. This figure reflects his position following the 6,000-share director stock option award disclosed in the transaction.

Is Fahed Al-Marzooqi’s vTv Therapeutics Form 4 transaction a market purchase or sale?

The Form 4 shows a grant coded “A,” meaning a grant, award, or other acquisition from the company, not an open-market trade. It represents compensation in the form of stock options rather than buying or selling shares in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Al-Marzooqi Fahed

(Last) (First) (Middle)

C/O VTV THERAPEUTICS INC.

3980 PREMIER DRIVE, SUITE 110

(Street)

HIGH POINT NORTH CAROLINA 27265

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
vTv Therapeutics Inc. [ VTVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director stock option (right to buy)	$35.08	06/26/2026		A		6,000		(1)	06/26/2036	Class A Common Stock	6,000	$35.08	19,555	D

Explanation of Responses:

1. The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting.

Remarks:

	/s/ Elizabeth Keiley, as Attorney-in-fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)